Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Aldose reductase and AGE inhibitors from Nissan Chem.

June 14, 1996

Troglitazone selected for NIDDK study

June 14, 1996

Antidiabetic agents reported by Boehringer Mannheim

June 14, 1996

rHb1.1 phase I trials begin in end-stage renal disease

June 14, 1996

SC-55494 effective in combination with rhG-CSF

June 14, 1996

CCK-A agonists revealed by Glaxo Wellcome

June 14, 1996

Warner-Lambert seeks approval for atorvastatin

June 14, 1996

Monsanto reveals benzothiazepines with novel activity

June 14, 1996

ACAT inhibitors from Sankyo

June 14, 1996

Hyperlipidemia treatment from Takeda

June 14, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 31, 2025
Vilastobart set apart? Xilio phase II combo performs in CRC
BioWorld
“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...
Novo weight-loss data roll out; Veru ‘leans’ in
BioWorld
As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line...
Appointments and advancements for Jan. 29, 2025
BioWorld
New hires and promotions in the biopharma industry, including: Allogene, Alumis, Beximco, Clarametyx, Commit, Concerto, OS Therapies, Precision, Roche, Scholar Rock.